Alexandria Hammond
Stock Analyst at B of A Securities
(1.84)
# 2,925
Out of 4,828 analysts
14
Total ratings
60%
Success rate
-5.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Upgrades: Buy | $35 → $63 | $39.75 | +58.49% | 2 | Jan 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $537.21 | +114.07% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $22.50 | +11.11% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $24.73 | +61.75% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $76.29 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $743.51 | +34.50% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $154.99 | +22.59% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $96.64 | +13.82% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $46.88 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $119.68 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $186.53 | +9.90% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $297.17 | -49.52% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $7.78 | +285.60% | 1 | Apr 22, 2024 |
Akero Therapeutics
Jan 30, 2025
Upgrades: Buy
Price Target: $35 → $63
Current: $39.75
Upside: +58.49%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $537.21
Upside: +114.07%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $22.50
Upside: +11.11%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $24.73
Upside: +61.75%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $76.29
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $743.51
Upside: +34.50%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $154.99
Upside: +22.59%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $96.64
Upside: +13.82%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $46.88
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $119.68
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $186.53
Upside: +9.90%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $297.17
Upside: -49.52%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $7.78
Upside: +285.60%